Serum Institute to launch Dengue Monoclonal in India in next two years.

The country’s largest vaccine manufacturer, Serum Institute of India, will be launching its dengue monoclonal in India by 2020 according to Adar Poonawala CEO, Serum Institute. Scientific details of the vaccine remained unclear. However, the vaccine maker said it will begin registrations for the vaccine soon. Serum Institute is also working on a 10-valent pneumococcal vaccine, which the company has patented in India has emerged as one of the key markets for the company as in the last four years, Poonawala said the government’s immunisation programme has helped doubled its revenue.

“Earlier, exports contributed to 90 per cent of our business, but now the share of the India market has gone up by 30 per cent ,” Poonawala told ET.

Serum Institute that recently formed the vaccine manufacturers association of India, a lobby group to speed by vaccine trials and use in the country, is looking to engage with government and researchers to speed up innovation. Currently, in this association, there are no multinational drug companies. The other vaccine companies part of it are Panacea Biotech (in which Serum owns equity), Bharat Biotech and Biological E.